Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy

Author(s):  Glaser Rebecca L, York Anne E

Issue:  Jul/Aug 2019 - Volume 23, Number 4
View All Articles in Issue

Page(s):  325-339

Note:  Electronic version includes supplemental material.

Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 1
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 2
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 3
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 4
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 5
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 6
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 7
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 8
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 9
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 10
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 11
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 12
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 13
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 14
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Page 15

Download in electronic PDF format for $75

Abstract:  This analysis was designed to determine the efficacy of anastrozole, an aromatase inhibitor, combined with testosterone in a subcutaneous implant in preventing elevated estradiol levels and the subsequent side effects of excess estrogen associated with testosterone therapy. It also allowed for the establishment of normative ranges of serum testosterone levels on subcutaneous implant therapy. The study participants were 344 men who were accrued to an institutional review board-approved cohort study between April 2014 and 2017. Efficacy of the subcutaneous combination implant in maintaining low estradiol levels was evaluated. Serum levels of testosterone and estradiol were measured throughout the implant cycle, at week 4, and when symptoms returned. Correlations between patient demographics, dosing, and serum levels on therapy were evaluated. Mean testosterone dose was 1827 ± 262 mg. Mean anastrozole dose was 15.3 ± 3.2 mg with the majority of men receiving 16 mg of subcutaneous anastrozole. The mean interval of insertion was 4.8 months. Low estradiol levels were maintained throughout the implant cycle. Mean T level at week 4 was 1183 ± 315 ng/dl and 553 ± 239 ng/dl when symptoms returned. Levels of testosterone on therapy inversely correlated with body mass index. There were no adverse events attributed to testosterone or anastrozole therapy. Subcutaneous anastrozole delivered simultaneously with testosterone allowed for higher dosing of testosterone and less frequent intervals of insertion. Low-dose anastrozole released from the combination implant maintained low estradiol levels throughout the implant cycle and prevented clinical side effects attributed to excess estrogen.

Related Keywords: Rebecca L. Glaser, MD, Anne E. York, MS, anastrozole, aromatase inhibitor, testosterone, high-dose testosterone, subcutaneous implant, estradiol level, adverse effects, estrogen level, clinical study, men

Related Categories: PEER-REVIEWED, ADVERSE DRUG EVENTS, DOSAGE FORMS/DRUG CARRIERS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy
Glaser Rebecca L
, York Anne E
Jul/Aug 2019
Pg. 325-339

Testosterone Levels in an Aging Population: Screen, Measure, and Restore
Kells John
, DollbaumCharles M
Mar/Apr 2011
Pg. 102-112

Poster Presentation Report: Safety of Maternal Testosterone Therapy During Breast Feeding
Glaser Rebecca L
, Newman Mark, Parsons Melanie, Zava David, Glaser-Garbrick Daniel
Jul/Aug 2009
Pg. 314-317

Compounded Testosterone Troches to optimize Health and the Testosterone Controversy
Guth Michael AS
May/Jun 2015
Pg. 195-203

Testosterone Deficiency in Men: New Treatments for Andropause
Biundo Bruce
, Shippen Eugene
Nov/Dec 2000
Pg. 429-431

Andropause: New Perspectives
Biundo Bruce
May/Jun 2004
Pg. 175-178

Compounded Testosterone Gels: A Guide for Clinicians and Pharmacists
Cutter Christopher B
Nov/Dec 2000
Pg. 432-437

View Sample
Quantitation of Testosterone Propionate in an Injection Using High Performance Liquid Chromatography
Gupta Vishnu D
Mar/Apr 1999
Pg. 158-159

Low-dose Naltrexone Therapy for Psoriasis
Weinstock Leonard B
, Cottel Jill, Aldridge Lindsey, Egeberg Alexander
Mar/Apr 2020
Pg. 94-96

Case Study: Absorption of Testosterone Cream via Scrotal Delivery
Needham Shawn
, Needham Shane
Nov/Dec 2018
Pg. 466-468

Testosterone Replacement Therapy for Female Androgen Insufficiency Syndrome
Tan Robert S
Jul/Aug 2005
Pg. 259-264

View Sample
Hormone Treatment Options for Males: What to Do for Men with Low Testosterone
Biundo Bruce
Jul/Aug 2009
Pg. 276-279

Testosterone Cypionate 100-mg/mL Injection
Allen Loyd V Jr
Jan/Feb 2013
Pg. 73

Testosterone Enanthate 200-mg/mL Injection
Allen Loyd V Jr
Mar/Apr 2014
Pg. 151

Measuring Testosterone Biomarkers in Serum and Saliva: Are They Accurate?
Tan Robert S
Nov/Dec 2004
Pg. 419-423

Quantitation of Testosterone-Cypionate-in-Oil Injection using High Performance Liquid Chromatography
Gupta Vishnu D
, Pramar Y
Jul/Aug 1999
Pg. 314-315

Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients
Sturn Kayla M
, Collin Michael
May/Jun 2016
Pg. 197-201

The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Stephenson Kenna
, Neuenschwander Pierre F, Kurdowska Anna K
Jan/Feb 2013
Pg. 74-85

View Sample
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders
Ploesser Jennifer
, Weinstock Leonard B, Thomas Erin
Mar/Apr 2010
Pg. 171-173

Establishing a Rationale for Compounding Hormone Replacement Therapy
Biundo Bruce
May/Jun 2018
Pg. 190-195

Return to Top